Caution and control of tuberculosis including co-infection with HIV in South Africa.

‘Bristol-Myers Squibb’s dedication to greatly help communities prevail over severe diseases is embodied in our Foundation’s mission to handle health disparities and empower communities,’ said Lamberto Andreotti, ceo, Bristol-Myers Squibb. Our work in HIV and TB co-contamination offers demonstrated the positive influence that community support can possess on tracking, follow-up of treatment and outcomes for infected individuals.’ The WHO will use its facilitation and brokering function with National TB and AIDS Control Programs to scale up community TB care in the five countries through strengthened engagement of nongovernmental and community structured organizations. WHO will promote the advancement of policies and applications that will enable higher involvement of NGOs and civil culture institutions in TB community care and the creation of a far more cost-effective and sustainable TB response.Astellas will also participate, along with Anokion’s existing investors, in a $16 Million equity funding for Kanyos. Anokion can be a biotechnology business developing products based on proprietary technology for the induction of antigen-specific immune tolerance. The technology targets antigens to the areas of red bloodstream cells in vivo; as the cells circulate, age and are cleared, the associated antigens are prepared using the immune program’s natural mechanisms to prevent autoimmunity. Anokion’s technology provides demonstrated the ability to induce immune tolerance to proteins drugs also to autoimmune antigens in pet models.

Other entries from category "hematology":

Random entries